Evernic and Diffractaic Acids Disrupt Redox Homeostasis, Inducing Distinct Cytotoxic Mechanisms in MCF-7 Breast Cancer Cells
Background
Oxidative stress is a critical driver of tumor development and cancer cell survival, yet the precise impact of natural compounds like lichen secondary metabolites on antioxidant defense systems remains underexplored. Cancer cells frequently upregulate key oxidoreductase enzymes such as thioredoxin reductase 1 (TrxR1) to maintain cellular redox balance. Previous work showed evernic acid (EA) and diffractaic acid (DA) inhibit TrxR1, exerting cytotoxic and anti-migratory effects in MCF-7 breast cancer cells. This study aimed to comprehensively investigate how EA and DA modulate oxidative stress and the antioxidant system.
Study Design
Researchers investigated the effects of evernic acid (EA) and diffractaic acid (DA) on MCF-7 breast cancer cells. They measured intracellular glutathione (GSH), reactive oxygen species (ROS), and malondialdehyde (MDA) levels. Additionally, they assessed the activities of various antioxidant enzymes, including superoxide dismutase (SOD), catalase (CAT), glutathione reductase (GR), glutathione peroxidase (GPX), and glutathione S-transferase (GST). Gene and protein expression of these enzymes were also evaluated to understand the molecular mechanisms underlying the observed redox changes. No specific doses or treatment durations were detailed in the abstract.
Results
Both evernic acid (EA) and diffractaic acid (DA) significantly disrupted cellular redox homeostasis in MCF-7 cells. They consistently decreased intracellular GSH levels and increased ROS accumulation. EA further elevated MDA levels, indicating increased lipid peroxidation, and caused a profound redox imbalance by suppressing the activity of multiple antioxidant enzymes: SOD, CAT, GR, GPX, and GST. In contrast, DA exhibited a more selective and balanced redox modulation, primarily inhibiting SOD, CAT, and GST activity while promoting apoptosis. The study concluded that EA specifically triggered ferroptosis-associated molecular alterations, primarily by disrupting the GSH-GPX4 axis. This suggests distinct mechanisms of cytotoxicity for the two compounds.
Evernic acid (EA) triggered ferroptosis-associated molecular alterations by disrupting the
GSH-GPX4axis, while diffractaic acid (DA) selectively inhibitedSOD,CAT, andGSTactivity, promoting apoptosis.
Key Findings
- Evernic acid (EA) and diffractaic acid (DA) disrupted redox homeostasis in MCF-7 breast cancer cells.
- Both EA and DA decreased intracellular
GSHand increasedROSlevels. - EA elevated
MDAlevels and suppressedSOD,CAT,GR,GPX, andGSTactivities. - DA selectively inhibited
SOD,CAT, andGSTactivity, promoting apoptosis. - EA triggered ferroptosis-associated molecular alterations by disrupting the
GSH-GPX4axis.
Why It Matters
This research highlights the therapeutic potential of lichen secondary metabolites, specifically evernic acid (EA) and diffractaic acid (DA), as novel redox-modulating agents for breast cancer. Understanding their distinct mechanisms—EA's induction of ferroptosis via the GSH-GPX4 axis and DA's selective antioxidant enzyme inhibition leading to apoptosis—could pave the way for more targeted cancer therapies. Developing compounds that specifically disrupt cancer cells' antioxidant defenses offers a promising strategy to overcome treatment resistance. While currently an in-vitro finding, it provides a strong rationale for further preclinical development, potentially leading to new drug candidates that exploit the unique metabolic vulnerabilities of cancer cells.
evernic-acid
diffractaic-acid
breast-cancer
mcf-7
oxidative-stress
redox-homeostasis